Pelthos Therapeutics Inc.

PTHS

AMEX

Healthcare

Biotechnology

Durham, NC, US4 employeespelthos.com

$20.40

-0.90(-4.23%)

Mkt Cap $13M

$11.70

$37.42

52-Week Range

At a Glance

AI-generated

Pelthos Therapeutics Inc.

Revenue breakdown: Net Product (96.5%), License And Collaboration (3.5%).

8-K

Pelthos Therapeutics Inc. announced fourth quarter and full year 2025 financial results via press release, reporting ZELSUVMI net product revenue of $9.1 million in Q4 (28% increase from Q3) and $16.2 million since July 2025 launch, with total 2025 revenue of $16.8 million. Highlights include acquisitions of XEPI in November 2025 and XEGLYZE in January 2026, $18 million convertible notes financing, and $30 million term loan draw.

$13M

Market Cap

—

Revenue

—

Net Income

Employees4

Fundamentals

How The Business Makes Money

Revenue by Segment

Net Product96.5%($16M)

License And Collaboration3.5%($589.0K)

Activity

What Changed Recently

Management Change

Jan 11, 2026

. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January

Financial Results

Mar 18, 2026

and Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, o

Material Agreement+4 More

Jan 12, 2026

. Entry into a Material Definitive Agreement. On January 12, 2026 (the “ Closing Date ”), Pelthos Therapeutics Inc., a Nevada corporation (the “ Company ”), LNH

Peer Companies

Company	Price	Change	Market Cap	P/E
LSTALisata Therapeutics, Inc.	$5.01	+0.10%	$45M	-2.6
CINGCingulate Inc.	$6.20	+3.08%	$35M	-1.7
PASGPassage Bio, Inc.	$8.18	+4.20%	$26M	-0.5
ENLVEnlivex Therapeutics Ltd.	$0.98	+1.78%	$24M	-2.1
LEXXLexaria Bioscience Corp.	$1.04	+20.08%	$20M	-1.4
LIXTLixte Biotechnology Holdi...	$3.14	+2.45%	$14M	-4.0
KAPAKairos Pharma, Ltd.	$0.59	+1.97%	$12M	—
MTVAMetaVia Inc.	$1.26	+0.80%	$3M	-0.2

Analyst View

Company Profile

CIK0001919246

ISINUS1711262048

Phone877 265 8266

Address4020 Stirrup Creek Drive, Suite 110, Durham, NC 27703, Durham, NC, 27703, US

SEC EDGAR